NEW YORK, August 3, 2015 /PRNewswire/ --
Equity Research Institute has initiated coverage on the
following equities: Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS),
Biogen Inc. (NASDAQ: BIIB), Array BioPharma Inc. (NASDAQ: ARRY),
Seres Therapeutics Inc. (NASDAQ: MCRB), and Athersys Inc. (NASDAQ:
ATHX). Free research report on Sunesis Pharma can be accessed at
https://www.EquityResearchInstitute.com/reports?keyword=SNSS On
Friday, July 31, 2015, the NASDAQ
Composite ended at 5,128.28, down 0.01%, the Dow Jones Industrial
Average edged 0.32% lower, to finish the day at 17,689.86, and the
S&P 500 closed at 2,103.84, down 0.23%. The gains were broad
based as five out of nine sectors ended the session in positive.
Register for your complimentary reports at the links given below.
Sunesis Pharmaceuticals Inc.'s stock lost 5.10%, to close the
day at $1.39. The stock recorded a
trading volume of 4.26 million shares, much above its three months
average volume of 2.14 million shares. Over the last one month and
over the past three months, Sunesis Pharmaceuticals Inc.'s shares
have plummeted 57.08% and 38.27%, respectively. Furthermore, the
stock has lost 45.29% since the start of this year. The company's
shares are trading 41.38% below their 200-day moving average.
Additionally, Sunesis Pharmaceuticals Inc. has a Relative Strength
Index (RSI) of 30.81. Sign up and read the free notes on SNSS
at:
https://www.EquityResearchInstitute.com/reports?keyword=SNSS
On Friday, shares in Biogen Inc. recorded a trading volume of
2.24 million shares, higher than their three months average volume
of 1.91 million shares. The stock ended the day 0.56% higher at
$318.78. Shares of the company traded
at a PE ratio of 21.57. Biogen Inc.'s stock has lost 21.37% in the
last one month, 17.46% in the previous three months and 6.09% on
YTD basis. The stock is trading below its 50-day and 200-day moving
averages by 18.18% and 15.13%, respectively. Furthermore, shares of
Biogen Inc. have an RSI of 29.82. The complimentary notes on BIIB
can be downloaded in PDF format at:
https://www.EquityResearchInstitute.com/reports?keyword=BIIB
Array BioPharma Inc.'s stock gained 1.04%, to close Friday's
session at $5.81. The stock recorded
a trading volume of 1.00 million shares, below its three months
average volume of 1.81 million shares. Over the last one month and
the previous three months, Array BioPharma Inc.'s shares have
declined 17.24% and 8.07%, respectively. However, the stock has
surged 22.83% since the start of this year. The company's shares
are trading 18.87% and 7.87% below their 50-day and 200-day moving
averages, respectively. Furthermore, Array BioPharma Inc.'s stock
has an RSI of 24.38. Register for free on Equity Research Institute
and access the latest research on ARRY at:
https://www.EquityResearchInstitute.com/reports?keyword=ARRY
Seres Therapeutics Inc.'s stock finished Friday's session 0.47%
lower at $37.85. A total of 0.16
million shares were traded, which was below its three months
average volume of 0.63 million shares. Over the last one month and
since the beginning of 2015, Seres Therapeutics Inc.'s shares have
lost 4.90% and 26.36%, respectively. The company's shares are
trading below their 50-day and 200-day moving averages by 7.23%,
each. The complete research on MCRB is available for free at:
https://www.EquityResearchInstitute.com/reports?keyword=MCRB
On Friday, shares in Athersys Inc. ended the session 1.87% lower
at $1.05. The stock reported a
trading volume of 0.60 million shares, close to its three months
average volume of 0.58 million shares. Athersys Inc.'s shares have
declined 13.22% in the last one month, 9.48% in the previous three
months and 33.54% on YTD basis. The stock is trading 14.30% below
its 50-day moving average and 39.32% below its 200-day moving
average. Moreover, shares of Athersys Inc. have an RSI of 30.84.
Free in-depth research on ATHX is available at:
https://www.EquityResearchInstitute.com/reports?keyword=ATHX
--
About Equity Research Institute:
Equity Research Institute ("ERI") produces regular sponsored and
non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ
and micro-cap stocks. ERI has two distinct and independent
departments. One department produces non-sponsored analyst
certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ERI has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"),
provides necessary guidance in preparing the document templates.
The Reviewer has reviewed and revised the content, as necessary,
based on sound investment judgment and publicly available
information which is believed to be reliable. The Reviewer and the
CFA® have not performed any independent investigations or forensic
audits to validate the information herein. Unless otherwise noted,
any content outside of this document has no association with the
Author, the Reviewer, or the CFA® (collectively referred to as the
"Production Team") in any way. The Production Team is compensated
on a fixed monthly basis and do not hold any positions of interest
in any of the securities mentioned herein.
NO WARRANTY
ERI, the Author, the Reviewer and the CFA® (collectively
referred to as the "Publishers") are not responsible for any error
which may be occasioned at the time of printing of this document or
any error, mistake or shortcoming. No liability is accepted by the
Publishers whatsoever for any direct, indirect or consequential
loss arising from the use of this document. The Publishers
expressly disclaim any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance
placed on the information in this document. Additionally, the
Publishers do not (1) guarantee the accuracy, timeliness,
completeness or correct sequencing of the information, or (2)
warrant any results from use of the information. The included
information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ERI nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
http://www.equityresearchinstitute.com.
RESTRICTIONS
ERI is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia. Do not send email to
robottrap (at) equityresearchinstitute.com.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.equityresearchinstitute.com